In this scenario, the intrahepatic environment during regeneration, markedly different from that of the quiescent liver, might impact on the efficacy of the GLP-1R agonist in ameliorating NAFLD. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.